Loss of exclusivity on several brands hurts AstraZeneca in Q1

Revenue contracted 12 per cent to 6.39bn dollar in the first quarter at FTSE 100-listed pharmaceuticals group AstraZeneca after losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada.

Revenue contracted 12 per cent to 6.39bn dollar in the first quarter at FTSE 100-listed pharmaceuticals group AstraZeneca after losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada.

The group reported that growth for Symbicort, Brilinta, Iressa and the inclusion of the Amylin diabetes products delivered more than $250m of revenue growth at constant exchange rates in the quarter.

Emerging Markets revenue increased by 9.0% at constant exchange rates (CER) in the quarter and core operating profit was down 21% at CER to $2.32bn in the first quarter.

The group said that the core operating profit decline had been driven by lower revenue and lower core other income, partially offset by core operating costs that were 4.0% lower at CER than last year.

Core earnings per share (EPS) was $1.41, down 21% at CER compared to the first quarter last year. This declined in line with core operating profit, as a higher tax rate this year was broadly offset by a lower number of shares outstanding and lower net finance expense, the group said.

AstraZeneca said that it continued to expect a mid-to-high single digit decline in revenue at CER and a core EPS decline that would be significantly larger than the decline in revenue for the full year.

Pascal Soriot, Chief Executive Officer of AstraZeneca, commented: "As anticipated, the first-quarter performance reflects the loss of exclusivity for several large products. We remain focused on our strategic priorities of returning to growth and achieving scientific leadership."

Soriot added: "Brilinta, the diabetes franchise, Emerging Markets, Japan and our Respiratory products have all made good progress and we continued to invest in distinctive science that will advance our knowledge of disease physiology and help to identify new drug targets."

MF

Recommended

Share tips of the week – 22 October
Share tips

Share tips of the week – 22 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
22 Oct 2021
Three dividend stocks from the dynamic Asia/Pacific region
Share tips

Three dividend stocks from the dynamic Asia/Pacific region

Professional investor Sat Duhra of the Henderson Far East Income investment trust highlights three of his favourite stocks.
18 Oct 2021
Share tips of the week – 15 October
Share tips

Share tips of the week – 15 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
15 Oct 2021
Trading: stash the family cash in this cheap wealth management firm
Trading

Trading: stash the family cash in this cheap wealth management firm

Wealth management is a growth market. Rathbone Brothers should be a prime beneficiary – and looks cheap. Matthew Partridge explains the best way to pl…
12 Oct 2021

Most Popular

How to invest as we move to a hydrogen economy
Energy

How to invest as we move to a hydrogen economy

The government has started to roll out its plans for switching us over from fossil fuels to hydrogen and renewable energy. Should investors buy in? St…
8 Oct 2021
How to invest in SMRs – the future of green energy
Energy

How to invest in SMRs – the future of green energy

The UK’s electricity supply needs to be more robust for days when the wind doesn’t blow. We need nuclear power, says Dominic Frisby. And the future of…
6 Oct 2021
The after effects of the gas-price shock
Economy

The after effects of the gas-price shock

In the wake of the recent spike in the natural gas price, we can expect slower growth, an industrial recession – and a newly assertive Russia, says Ma…
17 Oct 2021